PL378421A1 - Pochodne kwasu 10,10-dialkiloprostanowego jako środki do obniżania ciśnienia śródgałkowego - Google Patents

Pochodne kwasu 10,10-dialkiloprostanowego jako środki do obniżania ciśnienia śródgałkowego

Info

Publication number
PL378421A1
PL378421A1 PL378421A PL37842104A PL378421A1 PL 378421 A1 PL378421 A1 PL 378421A1 PL 378421 A PL378421 A PL 378421A PL 37842104 A PL37842104 A PL 37842104A PL 378421 A1 PL378421 A1 PL 378421A1
Authority
PL
Poland
Prior art keywords
agents
acid derivatives
intraocular pressure
glaucoma
prostanoic acid
Prior art date
Application number
PL378421A
Other languages
English (en)
Other versions
PL209130B1 (pl
Inventor
Yariv Donde
Jeremiah H. Nguyen
Original Assignee
Allergan, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/365,369 external-priority patent/US6875787B2/en
Application filed by Allergan, Inc. filed Critical Allergan, Inc.
Publication of PL378421A1 publication Critical patent/PL378421A1/pl
Publication of PL209130B1 publication Critical patent/PL209130B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Wynalazek dotyczy sposobu leczenia nadciśnienia śródgałkowego lub jaskry, polegającego na podawaniu pacjentowi cierpiącemu na nadciśnienie śródgałkowe lub jaskrę skutecznej ilości związku o ogólnym wzorze (I), w którym linia kreskowana oznacza ewentualnie obecne wiązanie, kreskowany klin oznacza konfigurację wiązania skierowanego w dół (α), pełny trójkąt oznacza konfigurację wiązania skierowanego w górę (β); n oznacza 0-6; X oznacza CH2, S lub O; Y oznacza ugrupowanie farmaceutycznie dopuszczalnej soli CO2H, lub CO2R, CONR2, CONHCH2CH2OH, CON (CH2CH2OH)2, CH2OR, P(O)(OR)2, CONRSO2R, i SONR2, albo 1-R-podstawiony tetrazolil-5; R oznacza H, C1-6-alkil lub C2-6-alkenyl; R2 i R3 oznaczają liniowe C1-6-alkile, takie same lub różne, które mogą być związane ze sobą z utworzeniem pierścienia zawierającego atom węgla, do którego są przyłączone.
PL378421A 2003-02-11 2004-02-06 Pochodne kwasu 10,10-dialkiloprostanowego, roztwór do stosowania w okulistyce, sposób wytwarzania związków pośrednich i zastosowanie pochodnych kwasu 10,10-dialkiloprostanowego PL209130B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/365,369 US6875787B2 (en) 2003-02-11 2003-02-11 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
US10/772,720 US20040235958A1 (en) 2003-02-11 2004-02-04 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure

Publications (2)

Publication Number Publication Date
PL378421A1 true PL378421A1 (pl) 2006-04-03
PL209130B1 PL209130B1 (pl) 2011-07-29

Family

ID=32871611

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378421A PL209130B1 (pl) 2003-02-11 2004-02-06 Pochodne kwasu 10,10-dialkiloprostanowego, roztwór do stosowania w okulistyce, sposób wytwarzania związków pośrednich i zastosowanie pochodnych kwasu 10,10-dialkiloprostanowego

Country Status (12)

Country Link
EP (1) EP1608309B1 (pl)
JP (1) JP5319065B2 (pl)
KR (1) KR101077461B1 (pl)
AU (1) AU2004211936B2 (pl)
BR (1) BRPI0407400A (pl)
CA (1) CA2515631C (pl)
MX (1) MXPA05008431A (pl)
NO (1) NO334659B1 (pl)
NZ (1) NZ541352A (pl)
PL (1) PL209130B1 (pl)
RU (1) RU2336081C2 (pl)
WO (1) WO2004071428A2 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7855226B2 (en) 2003-02-11 2010-12-21 Allergan, Inc. Treatment of inflammatory bowel disease
JP2008518013A (ja) * 2004-10-26 2008-05-29 アラーガン、インコーポレイテッド プロスタグランジンｅｐ４アゴニストによる処置方法およびデリバリー方法
AU2012200514B2 (en) * 2005-03-17 2014-03-06 Allergan, Inc. Treatment of inflammatory bowel disease
EP2084124B9 (en) * 2006-10-02 2015-07-01 Techfields Biochem Co. Ltd Positively charged water-soluble prodrugs of prostaglandins and related compounds with very high skin penetration rates
CN105566192B (zh) * 2006-10-02 2019-01-22 于崇曦 具有快速皮肤穿透速度的带正电荷的水溶性的前列腺素及相关化合物的前药
US8455547B2 (en) * 2008-02-05 2013-06-04 Allergan, Inc. Substituted cyclopentanes having prostaglandin activity
US7732443B2 (en) * 2008-03-18 2010-06-08 Yariv Donde Therapeutic substituted cyclopentanes
RU2500674C2 (ru) * 2008-05-09 2013-12-10 Аллерган, Инк. Терапевтические соединения
CN102655859A (zh) 2009-10-14 2012-09-05 格穆斯药业股份有限公司 病毒感染的组合疗法治疗
MX2013001227A (es) * 2010-07-30 2013-04-24 Allergan Inc Compuestos y metodos para reparacion de piel.
US20120046332A1 (en) * 2010-08-17 2012-02-23 Allergan, Inc. Compositions and methods for treating corneal haze
JP6694385B2 (ja) 2013-08-09 2020-05-13 アーデリクス，インコーポレーテッド リン酸塩輸送阻害のための化合物及び方法
CN114340631A (zh) 2019-05-21 2022-04-12 阿德利克斯股份有限公司 用于降低患者的血清磷酸盐的组合

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117014A (en) * 1976-01-09 1978-09-26 Abbott Laboratories Prostaglandin derivatives
JPS59101458A (ja) * 1982-12-01 1984-06-12 Nippon Iyakuhin Kogyo Kk 新規なチアプロスタグランジン誘導体及びその製法
JPS632972A (ja) * 1986-06-20 1988-01-07 Nippon Iyakuhin Kogyo Kk 新規プロスタグランジンｅ↓１誘導体及びその製法
US4994274A (en) * 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
US5034413A (en) * 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US5462968A (en) * 1994-01-19 1995-10-31 Allergan, Inc. EP2 -receptor agonists as agents for lowering intraocular pressure
US5877211A (en) * 1997-11-21 1999-03-02 Allergan EP2 receptor agonists as neuroprotective agents for the eye
US6410591B1 (en) * 2001-05-08 2002-06-25 Allergan Sales, Inc. 3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
US6531504B2 (en) * 2001-05-17 2003-03-11 Allergan, Inc. Prostanoic acid derivatives as agents for lowering intraocular pressure
WO2002102389A1 (en) * 2001-06-14 2002-12-27 Allergan, Inc. 3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure

Also Published As

Publication number Publication date
EP1608309A2 (en) 2005-12-28
JP5319065B2 (ja) 2013-10-16
NO20053715L (no) 2005-10-27
PL209130B1 (pl) 2011-07-29
WO2004071428A2 (en) 2004-08-26
CA2515631C (en) 2013-08-20
MXPA05008431A (es) 2005-10-19
NZ541352A (en) 2007-12-21
JP2006517587A (ja) 2006-07-27
NO20053715D0 (no) 2005-08-01
KR101077461B1 (ko) 2011-10-26
BRPI0407400A (pt) 2006-02-21
AU2004211936A1 (en) 2004-08-26
RU2336081C2 (ru) 2008-10-20
AU2004211936B2 (en) 2008-09-11
RU2005129072A (ru) 2006-02-27
CA2515631A1 (en) 2004-08-26
NO334659B1 (no) 2014-05-12
EP1608309B1 (en) 2012-07-11
WO2004071428A3 (en) 2005-11-10
KR20050101202A (ko) 2005-10-20

Similar Documents

Publication Publication Date Title
PL378421A1 (pl) Pochodne kwasu 10,10-dialkiloprostanowego jako środki do obniżania ciśnienia śródgałkowego
MY116542A (en) New inhibitors of platelet aggregation.
WO2002089813A3 (en) 3, 7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
WO2003094845A3 (en) Pyridine-based thyroid receptor ligands
LU91943I2 (fr) Tafluprost et ses dérivés pharmaceutiquement acceptables (SAFLUTAN®)
LU91162I2 (fr) Aloxi-Palonosétrone et ses dérivés pharmaceutiquement acceptables.
KR900701759A (ko) 비-펩타이드 레닌 억제제
EP0330461A3 (en) Piperidine derivatives
HK1049479A1 (zh) 降眼壓類脂類
NO20050470L (no) Aminoalkoholderivater
ATE268751T1 (de) Biphenylamidin-derivate
IL155965A0 (en) Pharmaceutical compositions containing an imidazole-5-carboxyclic acid derivative
DK1390036T3 (da) Prostansyrederivater som midler til nedsættelse af intraokulært tryk
AU2002346671B2 (en) Aminoalkyl-benzofuran-5-OL compounds for the treatment of glaucoma
EP0307061B1 (en) Anxiolytically active piperazine derivatives
JP2005513103A5 (pl)
US4558037A (en) Cardiovascular composition
US6127413A (en) Ocular depressor
TW200510395A (en) Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
EA200000373A2 (ru) Новые соединения 1-аза-2-алкил-6-арилциклоалкана, способ их получения и содержащие их фармацевтические композиции
DE3855824D1 (de) Anti-Plasmin Depressant
ES2354516T3 (es) Derivados de pirrolid-2-ona 1,5-disustituida para su uso como agonista del receptor de ep4 en el tratamiento de enfermedades oculares tales como glaucoma.
CA2151443A1 (en) Cycloheptimidazole derivatives, method of manufacturing the same and therapeutic agents containing these compounds
WO1998056379A1 (en) Compositions and methods for treating glaucoma
DE502005007939D1 (en) Enantiomerenreine hexahydropyrrolocyclopentapyridin-derivate

Legal Events

Date Code Title Description
RECP Rectifications of patent specification